5/7/2013 9:01:59 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
MORRIS PLAINS, N.J., May 7, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that it has received notice that its patent application for "Delivery system for cytotoxic drugs by bispecific antibody pretargeting," will issue as US patent No. 8,435,539 today.
Help employers find you! Check out all the jobs and post your resume.
comments powered by